74 related articles for article (PubMed ID: 2483121)
1. Human pulmonary natural killer (NK) cells exhibit limited lymphokine-activated killer (LAK) activity.
Yarbrough WC; Weissler JC
Am J Respir Cell Mol Biol; 1989 Oct; 1(4):305-11. PubMed ID: 2483121
[TBL] [Abstract][Full Text] [Related]
2. The heterogeneity of target recognition by lymphokine-activated killer precursor cells.
Ibayashi Y; Gray JD; Golub SH; Daibo M; Yamaki T; Kawahara T; Kubota T; Hashi K
Jpn J Cancer Res; 1990 Sep; 81(9):927-35. PubMed ID: 2121694
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets.
Chong AS; Aleksijevic A; Scuderi P; Hersh EM; Grimes WJ
Cancer Immunol Immunother; 1989; 29(4):270-8. PubMed ID: 2502310
[TBL] [Abstract][Full Text] [Related]
4. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
Furbert-Harris PM; Evans CH
Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
[TBL] [Abstract][Full Text] [Related]
5. Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms.
Funk J; Schmitz G; Failing K; Burkhardt E
Cancer Immunol Immunother; 2005 Jan; 54(1):87-92. PubMed ID: 15693143
[TBL] [Abstract][Full Text] [Related]
6. Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia.
Rajaram N; Tatake RJ; Advani SH; Naik SL; Gangal SG
Cancer Immunol Immunother; 1990; 31(1):44-8. PubMed ID: 2306755
[TBL] [Abstract][Full Text] [Related]
7. Human lymphokine-activated killer (LAK) cells: III. Effect of L-phenylalanine methyl ester on LAK cell activation from human peripheral blood mononuclear cells: possible protease involvement of monocytes, natural killer cells and LAK cells.
Leung KH
Cancer Immunol Immunother; 1991; 34(1):31-6. PubMed ID: 1760808
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic analyses of lymphokine-activated killer cells that release interferon gamma and tumor necrosis factor alpha.
Chong AS; Ybarrondo B; Grimes WJ; Hersh EM; Scuderi P
Cancer Immunol Immunother; 1990; 31(4):255-9. PubMed ID: 2143102
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells.
Klingemann HG; Wong E
Cancer Immunol Immunother; 1991; 33(6):395-7. PubMed ID: 1715237
[TBL] [Abstract][Full Text] [Related]
10. Modification of natural killer activity of lymphocytes infiltrating human lung cancers.
Anderson TM; Ibayashi Y; Holmes EC; Golub SH
Cancer Immunol Immunother; 1987; 25(1):65-8. PubMed ID: 3109739
[TBL] [Abstract][Full Text] [Related]
11. Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.
Scheid C; Young R; McDermott R; Fitzsimmons L; Scarffe JH; Stern PL
Cancer Immunol Immunother; 1994 Feb; 38(2):119-26. PubMed ID: 8306367
[TBL] [Abstract][Full Text] [Related]
12. The effects of staphylococcal protein A on human lymphokine-activated killer cell induction.
Lindemann RA; Singh KP; Shau H; Gupta RK
Cancer Immunol Immunother; 1991; 33(2):97-102. PubMed ID: 1709823
[TBL] [Abstract][Full Text] [Related]
13. Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.
Ruffini PA; Rivoltini L; Silvani A; Boiardi A; Parmiani G
Cancer Immunol Immunother; 1993 Jun; 36(6):409-16. PubMed ID: 8500113
[TBL] [Abstract][Full Text] [Related]
14. Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicity.
Park KG; Heys SD; Murray JB; Hayes PD; Ashby JA; Franks CR; Eremin O
Cancer Immunol Immunother; 1992; 35(1):53-8. PubMed ID: 1611623
[TBL] [Abstract][Full Text] [Related]
15. Soluble factors produced by macrophages/monocytes inhibit lymphokine-activated killer activity in rat splenocyte cultures.
Kuppen PJ; Eggermont AM; Quak RB; Marinelli A; van de Velde CJ; Fleuren GJ
Cancer Immunol Immunother; 1994 Jan; 38(1):61-7. PubMed ID: 8299120
[TBL] [Abstract][Full Text] [Related]
16. Large-scale preparation of adherent lymphokine-activated killer (A-LAK) cells for adoptive immunotherapy in man.
Melder RJ; Rosenfeld CS; Herberman RB; Whiteside TL
Cancer Immunol Immunother; 1989; 29(1):67-73. PubMed ID: 2785002
[TBL] [Abstract][Full Text] [Related]
17. Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. Characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation.
Fortis C; Ferrero E; Biffi M; Heltai S; Besana C; Bucci E; Tresoldi M; Rugarli C
Cancer Immunol Immunother; 1991; 33(2):128-32. PubMed ID: 2036660
[TBL] [Abstract][Full Text] [Related]
18. Cytostatic and cytotoxic activity of lymphokine-activated killer cell supernatants.
Hersh EM; Scuderi P; Grimes WJ; Chong A; Brailey JL; Gschwind CR; Salmon SE
Cancer Immunol Immunother; 1989; 30(1):65-70. PubMed ID: 2480843
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients.
Nanbara S; Arinaga S; Akiyoshi T
Cancer Immunol Immunother; 1989; 29(4):237-41. PubMed ID: 2568886
[TBL] [Abstract][Full Text] [Related]
20. Comparison of lymphokine-activated killer activities between thymocytes and splenocytes in rats with brain tumors.
Matsuura H; Imaya H
Cancer Immunol Immunother; 1991; 33(1):50-3. PubMed ID: 2021958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
